Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts

Biochemical and Biophysical Research Communications

Volumn 354, Issue 1, 2007, Pages 178-183

  Park, Hyojung ^a   Young Lee, Soo ^b   Lee, Dong Seok ^c   Yim, Mijung ^a  

^a Sookmyung Women's University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

COX 2; OPG; Osteoblast; Osteoclast; Parathyroid hormone; Phosphodiesterase 4; TRANCE

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN; ROLIPRAM;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FUNCTIONAL PROTEOMICS; GENE EXPRESSION REGULATION; GENE INDUCTION; GENOMICS; MALE; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION; MICE; MICE, INBRED ICR; OSTEOBLASTS; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHODIESTERASE INHIBITORS; RANK LIGAND; ROLIPRAM; SIGNAL TRANSDUCTION;

EID: 33846290960     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.174     Document Type: Article

References (23)

1. Väänänen H.K., Zhao H., Mulari M., and Halleen J.M. The cell biology of osteoclast function. J. Cell. Sci. 113 (2000) 377-381
2. Takahashi N., Akatsu T., Udagawa N., Sasaki T., Yamaguchi A., Moseley J.M., Martin T.J., and Suda T. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123 (1988) 2600-2602
3. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
4. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett III F.S., Frankel W.N., Lee S.Y., and Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272 (1997) 25190-25194
5. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., and Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 (1998) 3597-3602
6. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., and Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
7. Pilbeam C.C., Harrison J.R., and Raisz L.G. Prostaglandins and bone metabolism. In: Bilezikian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of Bone Biology (2002), Academic Press, New York 979-994
8. Li L., Pettit A.R., Gregory L.S., and Forwood M.R. Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name. Cytokine Growth Factor Rev. 17 (2006) 203-216
9. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., Saito S., Inoue K., Kamatani N., Gillespie M.T., Martin T.J., and Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103 (1999) 1345-1352
10. Chikazu D., Katagiri M., Ogasawara T., Ogata N., Shimoaka T., Takato T., Nakamura K., and Kawaguchi H. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J. Bone Miner. Res. 16 (2001) 2074-2081
11. Essayan D.M. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108 (2001) 671-680
12. Takami M., Cho E.S., Lee S.Y., Kamijo R., and Yim M. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett. 31 (2005) 832-838
13. Kondo H., Guo J., and Bringhurst F.R. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner Res. 17 (2002) 1667-1679
14. Tetradis S., Pilbeam C.C., Liu Y., Herschman H.R., and Kream B.E. Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic adenosine 3′,5′-monophosphate-mediated pathway in murine osteoblastic MC3T3-E1 cells. Endocrinology 138 (1997) 3594-3600
15. Dixon D.A., Balch G.C., Kedersha N., Anderson P., Zimmerman G.A., Beauchamp R.D., and Prescott S.M. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J. Exp. Med. 198 (2003) 475-481
16. Han S.Y., Lee N.K., Kim K.H., Jang I.W., Yim M., Kim J.H., Lee W.J., and Lee S.Y. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood 106 (2005) 1240-1245
17. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., and Pilbeam C.C. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J. Clin. Invest. 105 (2000) 823-832
18. Walsh M.C., and Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 14 (2003) 251-263
19. Ahlstrom M., and Lamberg-Allardt C. Regulation of adenosine 3′,5′-cyclic monophosphate (cAMP) accumulation in UMR-106 osteoblast-like cells: role of cAMP-phosphodiesterase and cAMP efflux. Biochem. Pharmacol. 58 (1999) 1335-1340
20. Tam C.S., Heersche J.N., Murray T.M., and Parsons J.A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110 (1982) 506-512
21. Kinoshita T., Kobayashi S., Ebara S., Yoshimura Y., Horiuchi H., Tsutsumimoto T., Wakabayashi S., and Takaoka K. Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone 27 (2000) 811-817
22. Waki Y., Horita T., Miyamoto K., Ohya K., and Kasugai S. Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models. Jpn. J. Pharmacol. 79 (1999) 477-483
23. Miyamoto K., Waki Y., Horita T., Kasugai S., and Ohya K. Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem. Pharmacol. 54 (1997) 613-617